BioPharmX Displays Progress in BPX-01 and BPX-04 Clinicals, Analyst Review and Target

Print
| Source: Traders News Source LLC

NEW YORK, NY, June 07, 2018 (GLOBE NEWSWIRE) -- Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on BioPharmX Corporation (NYSE American: BPMX), a pharmaceutical company that provides technologies for prescription, over-the-counter, and supplement applications in the health and wellness markets, including dermatology and women's health.

BioPharmX has successfully completed a phase 2b trial for BPX-01 and is preparing for phase 3 trials in acne. The company is currently conducting a feasibility study for BPX-04 in rosacea and is preparing for a phase 2 trial. When the company released clinical data for both products recently. The shares have seen some volatility.

Get a full pipeline clinical update and an analyst review and target price READ MORE
Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/biopharmx/

The past one year has been filled with numerous milestones for BioPharmX. The company achieved significant clinical milestones, including a successful Phase 2btrial for BPX-01 for acne and the launch of the BPX-04 rosacea program. Furthermore, BPMX was granted three patents from the United States Patent and Trademark Office with numerous patents pending.

Read about recent company highlights and get the Q4 and FYE financial data READ MORE
Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/biopharmx/

To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute

CONTACT:
Traders News Source
editor@tradersnewssource.com